Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959411 | 1.00 | TACR2 (0.43) | TACR2PTGDR2PPARGPPARDGRIK2 | |
| SCHEMBL3959416 | 1.00 | TACR2 (0.43) | TACR2PTGDR2PPARGPPARDGRIK2 | |
| SCHEMBL6693938 | 0.87 | TACR2 (0.40) | TACR2PTGDR2HCAR2HTR1AHTR1D | |
| SCHEMBL10204476 | 0.85 | TACR2 (0.40) | TACR2PTGDR2GRIK2HCAR2HTR1A | |
| SCHEMBL12369307 | 0.84 | CHRNB2 (0.37) | PPARGPPARDCHRNB2CHRNA4KMT2A | |
| SCHEMBL13068763 | 0.84 | TACR2 (0.39) | TACR2PTGDR2HTR1AHTR1DHTR1F | |
| SCHEMBL27739871 | 0.83 | CMA1 (0.42) | TACR2HTR1AHTR1DHTR1F | |
| SCHEMBL12363994 | 0.83 | CMA1 (0.42) | TACR2HTR1AHTR1DHTR1F | |
| SCHEMBL416746 | 0.83 | TACR2 (0.40) | TACR2PTGDR2MEN1KMT2A | |
| SCHEMBL27718829 | 0.81 | LMNA (0.38) | TACR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544685-B2 | 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2009-06-09 | — | — | US | disclosed |
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | HTR2C, HTR2A, HTR5A | TACR2 96/4885PTGDR2 57/4885PPARG 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.